Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-fast CD19 CAR-T in refractory systemic lupus erythematosus
NCT07331467Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in systemic lupus erythematosus (SLE), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety of CAR-T cell therapy in patients with refractory SLE at 3 months, Systemic Lupus Erythematosus Disease Activity Index 2000 at 6 months and 5 more. Started Jan 2026; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07331467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331467.